Documents

September 15, 2016

Our Best Shot: The Importance of Vaccines for Older Adults — Workshop Participant Evaluation

Our Best Shot: Workshop Kit is designed for community leaders hosting workshops for seniors and their caregivers on the basics of vaccination. The “soup-to-nuts” kit covers how vaccines work, common vaccine-preventable diseases, vaccine safety and efficacy, the vaccine schedule for adults 60-64 and 65+, and where and how to get vaccinated. 

This evaluation form is designed to collect valuable feedback from participants on the workshop.  Please use this feedback to adapt future workshops, and share with us at [email protected]. 

September 15, 2016

Our Best Shot: The Importance of Vaccines for Older Adults — Workshop Slide Presentation

Our Best Shot: Workshop Kit is designed for community leaders hosting workshops for seniors and their caregivers on the basics of vaccination. The “soup-to-nuts” kit covers how vaccines work, common vaccine-preventable diseases, vaccine safety and efficacy, the vaccine schedule for adults 60-64 and 65+, and where and how to get vaccinated.

The slide presentation adds visual interest to the discussion and elaborates on some of the concepts covered in the script.

September 12, 2016

Celebrating a Year Without a Stroke: Tips for you to simply talk with your atrial fibrillation patients about stroke prevention

The risk of stroke from atrial fibrillation (AFib) is real, and can quickly change a patient's life. As you know, the scientific evidence confirms that oral anticoagulation is highly effective at reducing stroke risk. Yet, elderly patients are too often under-anticoagulted, owing in part to their lack of understanding about stroke risk and the value of anticoagulation. This tip sheet offers talking points to help health care professionals help their patients to better understand why anticoagulation is critical and how adherence will allow them to celebate more years without a stroke.

August 30, 2016

Heart Valve Disease Awareness Surveys

The Alliance for Aging Research has released surveys that give insights into public awareness about heart valve disease. 

August 23, 2016

Alliance Comments on PDUFA VI Commitment Letter

The Alliance provided comments in response to the U.S. Food and Drug Administration's PDUFA VI Commitment Letter.

August 15, 2016

Comments on CMS-3295-P by the Alliance

The Alliance for Aging Research submitted comments to the Centers for Medicare and Medicaid Services (CMS) on its proposal rule: CMS-3295-P, Medicare and Medicaid Programs; Hospital and Critical Access Hospital (CAH) Changes to Promote Innovation, Flexibility, and Improvement in Patient Care.

June 10, 2016

OTC Monograph User Fee Public Meeting Remarks

These are remarks made by Alliance Vice President of Public Policy Cynthia Bens at the U.S. Food and Drug Administration's public meeting on OTC Monograph User Fees on June 10, 2016.

June 1, 2016

Malnutrition: Healthcare Professional Tip Sheet

Many cases of malnutrition go undetected because the signs are subtle, those at risk are often difficult to recognize, and the symptoms may look like a normal part of aging.  This tip sheet helps healthcare professionals identify at-risk patients, screen for malnutrition, and personalize a treatment plan if necessary.  The tear-off section is for patients and includes additoinal resources and information.

May 19, 2016

The Silver Book: Diabetic Retinopathy Factsheet

The Alliance for Aging Research released The Silver Book®: Diabetic Retinopathy, a factsheet that gives an overview of the threat the eye disease presents to global health.

March 17, 2016

FY17 ACT-AD FDA Appropriations Request Letter

Letter to the House and Senate Appropriations Subcommittees on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies urging the Subcommittee to prioritize the U.S. Food and Drug Administration's (FDA) during Fiscal Year (FY) 2017 by increasing the agency's appropriated funding by $120 million. 

March 14, 2016

AVAC Medicare Advantage Part D Letter

The Alliance for Aging Research signed on to a letter from Adult Vaccine Access Coalition (AVAC) on the Medicare Advantage Part D Advance Notice and Draft Call Letter. 

March 7, 2016

FY17 AVAC Appropriations Request Letter

Letter to the House and Senate Labor, Health and Human Services, Education, and Related Agencies Appropriations Subcommittees, urging the Subcommitees to prioritize funding for adult immunization related activities at the Department of Health and Human Services (HHS) for FY2017. 

March 7, 2016

Comments on NHLBI Draft Strategic Research Priorities

Letter to the Office of Science Policy, Engagement, Education, and Communications (OSPEEC) at the National Heart, Lung, and Blood Institute (NHLBI) urging the Institute to include the Afib Optimal Treatment Task Force's critical challenge of developing an effective integrated bleeding risk assessment tool as part of the NHLBI's final Strategic Research Priorities. 

March 6, 2016

Senate HELP Combination Products Letter

Letter from the Alliance for Aging Research applauding the Senate Health, Education, Labor, and Pensions Committee's efforts in addressing the ways in  which combination products are reviewed by the U.S. Food and Drug Administration (FDA). 

February 23, 2016

S-FAR’s PATH Act Letter

The Alliance for Aging Research signed onto the U.S. Stakeholder Forum for Antibiotic Resistance (S-FAR) sign-on letter for the Senate HELP Committee, supporting S.185, the Promise for Antibiotics and Therapeutics for Health (PATH) Act. 

February 22, 2016

Coalition for Health Funding Letter

The Alliance for Aging Research signed on to a Coalition for Health Funding letter in support of increasing the Departments of Labor, Health and Human Services, and Education and related agencies appropriations subcommittee, to increase the 302(b) allocations for the agencies under the subcommittee's jurisdiction. 

January 29, 2016

AFib Multiple Chronic Conditions Letter

Letter from the Afib Optimal Treatment Task Force commenting on the efforts of the Senate Finance Committee's working group on multiple chronic conditions (MCC) policy options white paper.

January 26, 2016

MCC Working Group Comment Letter

January 12, 2016

Comment Letter on CDC Opioid Guidelines

The Alliance for Aging Research wrote a letter to the Centers for Disease Control and Prevention (CDC) requesting modifications to the 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain. Specifically, the Alliance recommended the CDC modify the guidelines by: 

Including a statement calling for further investment of federal resources into clinical research to assist providers in tailoring long-term opioid use.
Requiring Department of Health and Human Services (HHS) to provide an updated clinical evidence review of the guidelines
Calling on public and private payers to broadly cover the cost of non-pharmacologic interventions for pain sufferers. 
Adding more resources to www.cdc.gov on the safe use of non-opioid pain treatment
Removing the non-evidenced based dosage recommendations
Removing the time/specific pill limit for acute pain treatment

January 5, 2016

Alzheimer’s Disease PCORI Priorities Letter

The Alliance for Aging Research submitted a letter to the Patient-Centered Outcomes Research Institute (PCORI) suggesting possible research for the Institute to consider, aimed at improving outcomes for people with Alzheimer's disease. The Alliance encouraged the following topics:

Impact of non-pharmacologic interventions for Alzheimer’s disease on patient outcomes, caregiver burden and rates of institutionalization
Evaluation of screening methodologies, for relative ease/uptake and associated optimization across provider groups and settings of care;
Assessment of how Alzheimer’s disease diagnosis and treatment affects management of comorbidities;
Frequency of emergency room visits for Alzheimer’s disease patients and identification of
best practices for potential mitigation;
Comparisons of currently available tools used to assess cognition to identify which is most
effective for specific populations; and
Impact of knowing positive ApoE genotype status on patient, caregiver, and provider
behaviors/outcomes as compared to ApoE negative status.